CARL ZEISS MEDITEC AG 'We are delighted to provide doctors now with improved fundus cameras that support fast and reliable diagnosis and follow-up of challenging retinal eye diseases like dry AMD, glaucoma and diabetic retinopathy through brilliant pictures that offer more details' says Dr. Ludwin Monz, Chief Executive Officer of Carl Zeiss Meditec AG. 'The new Fundus Cameras are part of our comprehensive retinal and glaucoma solution that, combined with the CIRRUS HD-OCT, provide doctors with complete information on the retina and optic disc.'
Backed by an internal 24 MP sensor, a newly designed optical system and enhanced post-processing for fast and informative imaging, the fundus cameras produce unprecedented image quality from a non mydriatic design. At the same time, the system is easy to use. Both new VISUCAM models include Fundus Autofluorescence (FAF) as a standard feature to support current and emerging therapeutic management options for dry AMD. Other standard modalities such as color and red-free enhance the visualization of different anatomical features. Thanks to superior image quality, pictures taken by the new cameras also facilitate patient education.
The new VISUCAM 524 will also offer Fluorescein Angiography and optional Indocyanine Green Angiography for the assessment of vascular blood flow and leakage.
VISUCAM 224 / 524 is available in the US, Canada, the European Union and throughout Asia.
The portable fundus camera VISUSCOUT® 100 for retinal examinations
Also part of the ophthalmic portfolio of ZEISS is the mobile fundus camera VISUSCOUT® 100. This especially light and compact device, designed to bring retina imaging to smaller practices and mobile ophthalmic stations, is equipped with strong batteries for mobile use. It is part of the Essential Line of ZEISS and was recently awarded a Red Dot award for good product design.
ZEISS has a long tradition in advancing technology to examine the back of the eye: In 1926 Johan Nordenson and ZEISS made the first modern fundus camera commercially available for use by practitioners and the first fluorescein angiography (FFA) in 1959 was performed using a ZEISS fundus camera.
Jann Gerrit Ohlendorf
Director Corporate Communications
Carl Zeiss Meditec AG
Phone: +49 3641 220-331
Fax: +49 3641 220-332
press.meditec@zeiss.com
Sebastian Frericks
Director Investor Relations Carl Zeiss Meditec AG
Carl Zeiss Meditec AG
Phone: +49 3641 220-116
investors.meditec@.zeiss.com
Carl Zeiss Meditec AG
Carl Zeiss Meditec AG (ISIN: DE0005313704), which is listed on TecDax of the German stock exchange, is one of the world's leading medical technology companies. The company supplies innovative technologies and application-oriented solutions designed to help doctors improve the quality of life of their patients. It provides complete packages of solutions for the diagnosis and treatment of eye diseases, including implants and consumables. The company creates innovative visualization solutions in the field of microsurgery. The company's medical technology portfolio is rounded off by promising, future-oriented technologies such as intraoperative radiotherapy.
In fiscal year 2013/14 (ended 30 Sept) the around 3,000 employees of the Carl Zeiss Meditec Group generated revenue of EUR 909 million.
The company headquarters are located in Jena, Germany. The company has subsidiaries in Germany and abroad; more than 50 percent of its employees are based in the USA, Japan, Spain and France. The Center for Application and Research in India (CARIn) in Bangalore, India, and the ZEISS Innovation Center for Research and Development in Shanghai, China, strengthen the company's presence in these fast-growing countries. Around 35 percent of Carl Zeiss Meditec AG shares are in free float. The remaining approx. 65% are held by Carl Zeiss AG, one of the world's leading companies in the optical and optoelectronic industries.
For more information visit our website at:
www.zeiss.com/med
Number: 0143-2015-ENG OP
Number of Words: 401
Number of Characters: 2697
|
distributed by
|
